Immediate Impact

35 standout
Sub-graph 1 of 16

Citing Papers

Tumor biomarkers for diagnosis, prognosis and targeted therapy
2024 Standout
Invasive pneumococcal disease 3 years after introduction of a reduced 1 + 1 infant 13-valent pneumococcal conjugate vaccine immunisation schedule in England: a prospective national observational surveillance study
2024 Standout
1 intermediate paper

Works of Allison Thompson being referenced

Estimated net benefit of avelumab (AVE) + best supportive care (BSC) vs BSC alone for patients (pts) with advanced urothelial carcinoma (aUC) using a quality-adjusted time without cancer symptoms or toxicity (Q-TWiST) analysis.
2023
Streptococcus pneumoniae serotype 15B polysaccharide conjugate elicits a cross-functional immune response against serotype 15C but not 15A
2022

Author Peers

Author Last Decade Papers Cites
Allison Thompson 467 20 176 43 37 554
Joana Saldanha 479 21 238 109 35 603
Conchita Izquierdo 479 8 134 40 43 572
Joyce U. Nyiro 396 33 136 82 23 466
Ilias Galanis 502 15 195 31 28 610
Gail L. Rodgers 502 27 174 48 30 645
Christian B. Ramers 305 92 67 64 40 614
Adegoke G. Falade 287 22 106 99 19 471
Takaya Maruyama 456 20 74 37 19 542
Erin L. Murray 353 16 152 64 24 606
Hanna Rinta‐Kokko 512 7 243 65 26 573

All Works

Loading papers...

Rankless by CCL
2026